95 related articles for article (PubMed ID: 16433042)
21. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo.
Chen H; Takahashi S; Imamura M; Okutani E; Zhang ZG; Chayama K; Chen BA
Chin Med J (Engl); 2007 May; 120(10):898-904. PubMed ID: 17543180
[TBL] [Abstract][Full Text] [Related]
22. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
[TBL] [Abstract][Full Text] [Related]
23. Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells.
Wesołowska O; Michalak K; Błaszczyk M; Molnár J; Środa-Pomianek K
Molecules; 2020 Apr; 25(7):. PubMed ID: 32260260
[TBL] [Abstract][Full Text] [Related]
24. Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro.
Huang Z; Guo KJ; Guo RX; He SG
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):312-20. PubMed ID: 17548258
[TBL] [Abstract][Full Text] [Related]
25. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.
Huang L; Wang C; Zheng W; Liu R; Yang J; Tang C
Anticancer Drugs; 2007 Oct; 18(9):1075-80. PubMed ID: 17704658
[TBL] [Abstract][Full Text] [Related]
26. Cinnamylidene ketones as potential modulators of multidrug resistance in mouse lymphoma and human colon cancer cell lines.
Engi H; Gyémánt N; Lóránd T; Lévai A; Ocsovszki I; Molnár J
In Vivo; 2006; 20(1):119-24. PubMed ID: 16433039
[TBL] [Abstract][Full Text] [Related]
27. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
28. Elimination of plasmids by SILA compounds that inhibit efflux pumps of bacteria and cancer cells.
Schelz Z; Martins M; Martins A; Viveiros M; Molnar J; Amaral L
In Vivo; 2007; 21(4):635-9. PubMed ID: 17708358
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
30. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of a new gene P28GANK confers multidrug resistance of gastric cancer cells.
Li X; Zhang Y; Xiong C; Jin H; Jing B; Zhang Y; Fan D
Cancer Invest; 2009 Feb; 27(2):129-39. PubMed ID: 19235584
[TBL] [Abstract][Full Text] [Related]
32. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
33. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
34. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
35. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
36. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
37. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Li J; Lindner DJ; Farver C; Borden EC; Yi T
Cancer Chemother Pharmacol; 2007 Aug; 60(3):341-9. PubMed ID: 17103170
[TBL] [Abstract][Full Text] [Related]
40. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
